BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

Atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) and chronic kidney
disease (CKD) are major complications of type 2 diabetes (T2DM). The objectives of …

Purpose Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and now tirzepatide, a dual
GLP-1 RA/glucose-dependent insulinotropic polypeptide agonist, have numerous …

Few pharmacologic advances in cardiometabolic medicine have been as impactful as
sodium-glucose cotransporter-2 (SGLT2) inhibitors. Initially developed as glucose-lowering …

Background Research on diabetes remission has garnered prominence in recent years.
However, to date, no pertinent bibliometric study has been published. This study sought to …

BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP1-RAs) and sodium
glucose cotransporter 2 inhibitors (SGLT2is) have proven benefits in patients with type 2 …

Background People with type 2 diabetes (T2D) are at elevated risk of cardiovascular
disease (CVD) including stroke, yet existing real-world evidence (RWE) on the clinical and …

Aim Given a lack of data on diabetes care performance in Malaysia, we conducted a cross-
sectional study to understand the clinical characteristics, control of cardiometabolic risk …

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are recommended for type 2 diabetes
mellitus patients with impaired renal function, but the actual situation of SGLT2i using is …

Aims To describe glucose-lowering drugs prescribing pattern in a large population of older
diabetics from 2010 to 2021. Methods Using linkable administrative health databases, we …